Mannkind (MNKD.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec23

MannKind FUROSCIX® On-body Infusor Approved by FDA

13:07

MannKind Announces Five New US Patents for FUROSCIX ReadyFlow Autoinjector

13:05

Dec5

Michael Castagna, CEO of MannKind Corp., Reports Disposal of Common Stock

00:33

MannKind Corp's VP sells company stocks

00:31

Dec1

MannKind Corp's FUROSCIX ReadyFlow Autoinjector sNDA Accepted by FDA

13:05

Nov12

Wells Fargo Reiterates Buy Rating on MannKind

11:19

Schedules & Filings

Schedules

Filings

Nov5

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 82.13 M, Net Income 7.985 M, EPS 0.026

Aug6

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 76.53 M, Net Income 668 K, EPS 0.0021

May8

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 78.35 M, Net Income 13.16 M, EPS 0.0418

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More